Bernstein Harold sold $435K of MAZE
Bernstein Harold (President, R&D & CMO) sold 16,141 shares of Maze Therapeutics, Inc. (MAZE) at $26.93 ($0.43M total) on 2026-10-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is the first public filing of this transaction, providing new information to the market.
Market read
A modest insider sell by a senior executive, likely to cause only a slight, short‑term price dip.
What to watch
Potential upcoming clinical data releases or partnership news could offset any negative sentiment from the insider sell.
Background
Maze Therapeutics is a biotech firm developing therapies for metabolic diseases. Insider transactions are regularly monitored for signals.
Ticker impact
Form 4 disclosed President Harold Bernstein sold 16,141 shares for $434,743, reducing his holding to zero.
likely slight downward pressure as the market prices the insider sale
The sale is under $1M and represents a complete exit by a senior executive, which can be viewed as a mild bearish signal, but the amount is small relative to float.
Market effects
Minimal effect on biotech sector; insider sales are common and unlikely to shift sector sentiment.
No regional impact; confined to the company's shareholders.
Limited global relevance; only affects Maze Therapeutics investors.
Counterpoint
The sale could be a routine liquidity event unrelated to company fundamentals, so price may remain unchanged.
Key entities
- PersonHarold Bernstein
President, R&D & CMO of Maze Therapeutics, reported insider sale.
- CompanyMaze Therapeutics, Inc.
Biotech company listed on Nasdaq under ticker MAZE.
